UTILIZATION OF GENE-ENGINEERED T CELLS FOR ENHANCING CANCER IMMUNOTHERAPY

Grant number: 1041828 | Funding period: 2013 - 2017

Completed

Abstract

Killer T lymphocytes can penetrate tumours and their transfer into cancer patients has demonstrated some encouraging results, but this form of therapy and other approaches including vaccination remain ineffective in most cancer patients. In this project, we propose to improve the tumour trafficking and anti-tumour activities of killer cells by genetically engineering them with proteins that will enable them to recognise and destroy cancer cells, whilst minimizing toxicity to normal tissue.

Related publications (11)

Researchers